Dyslipidemia in Type 2 Diabetes: What's the Role of Combination Drugs?

Diabetes is a strong risk factor for cardiovascular (CV) events and death. It is associated with a two-to-four-fold increased risk of cardiovascular disease (CVD), causing up to 80% of deaths in people with diabetes. The control of blood glucose, blood pressure and lipids is among the 2003 Canadian Diabetes Guidelines’ highest-priority mandated measures for vascular protection. Those patients who are young, with shorter duration of diabetes, no other CVD risk factors and no other complications of diabetes may be considered at moderate risk (Table 1). The most common lipid abnormality in diabetes is high triglyceride (TG) and low highdensity lipoprotein (HDL) cholesterol (HDL-C) levels. Although low-density lipoprotein (LDL) cholesterol (LDL-C) may not be elevated, an increased proportion of LDL has been found to be of the more pro-atherogenic, small, dense variety. This lipid profile contributes to the high prevalence of metabolic syndrome in patients with Type 2 diabetes and shares many of its pathophysiological features. The primary abnormality of metabolic syndrome is the liver’s over-production of very low-density lipoprotein (VLDL), the major TG-carrying particles and precursor of the more cholesterolenriched LDL. The breakdown of TG by the enzyme called lipoprotein lipase may also be partially impaired, contributing to the high level of TG. The VLDL in the circulation interacts with HDL and LDL and exchanges their lipid contents through an enzyme called cholesterol-ester transfer protein. Excess TG in VLDL is transferred to both HDL and LDL in exchange for cholesterol; as a result, the excess TG-in HDL are broken down by an enzyme called hepatic lipase (HL), resulting in accelerated clearance of HDL and a low level of HDL-C. The excess TG in LDL is also broken down by HL, transforming them into small, dense LDL. Small, dense LDL is cleared more slowly by the liver through the LDL receptor, more readily enters arterial walls, induces more endothelial dysfunction and is more susceptible to oxidation. This vicious cycle creates the atherogenic triad of small, dense LDL, high TG and low HDL. Three classes of medications are commonly used to treat dyslipidemia in patients with diabetes: HMG-CoA reductase inhibitors (statins), fibric acid derivatives and niacin.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.